2018, Number 3
Determination of mutations (del E746-A750 exon 19 and L858R exon 21) in the epidermal growth factor receptor (EGFR) gene in serum samples and in biopsys of non-microcytic lung carcinoma (NMLC)
Full text
Language: Spanish
References: 18
Page: 71-79
PDF size: 256.99 Kb.
ABSTRACT
Introduction. EGFR mutations, del E746-A750 in exon 19 and L858R in exon 21 in tumor cells of NMLC represent biomarkers of response to tyrosine kinase inhibitors (TKI) therapy. Patients with tumors positive for EGFR mutations show better response and greater survival. These mutations occupy 90% of mutations in lung cancer.Objective. To evaluate the frequency of mutations del E746-A750-exon 19 and L858R-exon 21 of EGFR gene in NMLC biopsy samples and in serum samples of the general population from Yucatán.
Material and methods. 19 NMLC biopsy samples of adenocarcinoma type and 101 serum samples from healthy subjects were selected. EGFR mutations del E746-A750 and L858R were determined by allele-specific PCR amplification (PCR-ASO). The genotypic and allelic frequencies; and their distribution according to Hardy Weinberg expectations were calculated using the SNPstats software.
Results. For serum, EGFR del E746-A750 mutation, homozygous genotype (1/1) was present in 26.58%, heterozygote (1/0) in 73.42% and absence of mutant genotype with deletion (0/0); whereas for L858R mutation, 21.78% were homozygous (TT), 54.46% heterozygous (T/G) and 23.76% GG mutants. For the NMLC biopsies, the heterozygote was the most frequent genotype for both mutations, 63.16% and 73.68% for del E746-A750 and L858R, respectively.
Conclusion. The frequency of mutations of EGFR gene in serum samples was 36.71% for deletion delE746-A750 in exon 19 and 50.99% for L858R in exon 21. Distribution of mutations in biopsy samples NMLC resulted in 42.11% for each EGFR mutation.
REFERENCES
Arrieta O, Ramirez-Tirado LA, Báez-Saldaña R, Peña- Curiel O, Soca-Chafre G, Macedo-Perez EO. Different mutation profiles and clinical characteristics among Hispanic patients with non-small cell lung cancer could explain the “Hispanic paradox”. Lung Cancer. 2015 Nov; 90(2): 161-6. DOI: https://doi.org/10.1016/j. lungcan.2015.08.010.
Arrieta O, Cardona A, Corrales L, Campos-Parra AD, Sánchez-Reyes R, Amieva-Rivera E, et al. The impact of common and rare EGFR mutations in response to EGFR tyrisine kinase inhibitors and platinum-based chemotherapy in patients with non-small cell lung cáncer. Lung Cancer. 2015 Feb; 87(2): 169-75. DOI: https://doi.org/10.1016/j.lungcan.2014.12.009.
Kimura H, Kasahara K, Kawaishi M, Kunitoh H, Tamura T, Holloway B, et al. Detection of Epidermal Growth Factor Receptor Mutations in Serum as a Predictor of the Response to Gefitinib in Patients with Non −Small- Cell Lung. Clin Cancer Res. 2006 July; 12(13): 3915-21. DOI: https://doi.org/10.1158/1078-0432.CCR-05-2324.
Otero J, Cardona A, Reveiz L, Campo F, Carranza H, Vargas C; et al. Supervivencia en pacientes con adenocarcinoma de pulmón metastásico y registro de las primeras mutaciones en el receptor para el factor de crecimiento epidérmico documentado en Colombia. Acta Med Colomb. 2009 Abril-Junio; 34(2): 55-65.
Kimura H, Nishikawa S, Koba H, Yoneda T, Sone T, Kasahara K. A Rapid and Sensitive Method for Detection of the T790M Mutation of EGFR in Plasma DNA. In: Gahan P., Fleischhacker M., Schmidt B. (eds) Circulating Nucleic Acids in Serum and Plasma – CNAPS IX. Advances in Experimental Medicine and Biology. Springer, Cham 2016.vol 924. DOI: https://doi. org/10.1007/978-3-319-42044-8_31.